Bg pattern

FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Fasenra 30mg solution for injection in pre-filled pen

benralizumab

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Fasenra and what is it used for
  2. What you need to know before you use Fasenra
  3. How to use Fasenra Pen
  4. Possible side effects
  5. Storing Fasenra Pen
  6. Contents of the pack and other information

1. What is Fasenra and what is it used for

What is Fasenra

Fasenra contains the active substance benralizumab, which is a monoclonal antibody, i.e. a type of protein that recognizes and binds to a specific substance in the body. The target of benralizumab is a protein called interleukin-5 receptor, which is found particularly in a type of white blood cell called an eosinophil.

What is Fasenra used for

Asthma

Fasenra is used to treat severe eosinophilic asthma in adults. Eosinophilic asthma is a type of asthma where patients have too many eosinophils in their blood or lungs.

Fasenra is used in addition to other medicines for asthma (high doses of ‘inhaled corticosteroids’ plus other anti-asthma medicines) when the disease is not well controlled by these other medicines alone.

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Fasenra is used to treat EGPA in adults. EGPA is a disease where people have too many eosinophils in their blood and tissues and also have some form of vasculitis. This means there is inflammation of the blood vessels. This disease most commonly affects the lungs and the sinuses, but often affects other organs such as the skin, heart, and kidneys.

How Fasenra works

Eosinophils are white blood cells involved in the inflammation of asthma and EGPA. By binding to eosinophils, Fasenra helps to reduce their number and inflammation.

Benefits of using Fasenra

Asthma

Fasenra may reduce the frequency of asthma attacks you are experiencing, helping you to breathe better and reducing your asthma symptoms. If you are using medicines called ‘oral corticosteroids’, using Fasenra may also allow you to reduce the daily dose or stop treatment with oral corticosteroids you need to control your asthma.

EGPA

Fasenra may reduce the symptoms and prevent flare-ups of EGPA. This medicine may also allow you to reduce the daily dose of oral corticosteroids you need to control your symptoms.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Fasenra

Do not use Fasenra:

  • If you are allergicto benralizumab or any of the other ingredients of this medicine (listed in section 6). Talk to your doctor, nurse or pharmacistif you think this applies to you.

Warnings and precautions

Talk to your doctor, nurse or pharmacist before using Fasenra:

    parasitic infectionor live in an area where parasitic infections are common or travel to such an area. This medicine may reduce your ability to fight certain types of parasitic infections.allergic reaction to an injection or medicine in the past(see section 4 for symptoms of an allergic reaction).

Also, talk to your doctor, pharmacist or nurse if you are receiving Fasenra:

    asthma remains uncontrolled or worsensduring treatment with this medicine.allergic reaction(see section 4). Allergic reactions have occurred in patients receiving this medicine.

Fasenra is not a rescue medicine. Do not use it to treat a sudden asthma attack.

Be aware of the signs of serious allergic reactions

Fasenra may potentially cause serious allergic reactions. You should be aware of the signs of these reactions (such as hives, skin rash, difficulty breathing, fainting, discomfort, feeling dizzy and/or swelling of the face, tongue or mouth) while you are receiving Fasenra.

It is important that you talk to your doctor about how to recognize the early symptoms of serious allergic reactions and how to manage them if they occur.

In order to improve the traceability of biological medicinal products, the name and batch number of the product should be clearly recorded in the patient file each time the product is administered, and this information should be reported in case of any adverse reaction.

Other medicines for asthma or EGPA

Do not suddenly stopor change the dose of your other medicines for your disease when you start Fasenra.

If your response to treatment allows, your doctor may try to reduce the dose of some of these medicines, especially those called "corticosteroids". This should be done gradually and under the direct supervision of your doctor.

Tell your doctorif you are using, have recently used, or might use any other medicines before using Fasenra.

Children and adolescents

Do not give this medicine to children under 18 years old because the safety and benefits of this medicine in this population are not known.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctorfor advice before using this medicine.

Do not use Fasenra if you are pregnant unless your doctor tells you to. It is not known if Fasenra can affect the fetus.

It is not known if the components of Fasenra can pass into breast milk. Talk to your doctorif you are breast-feeding or plan to breast-feed.

Driving and using machines

Fasenra is unlikely to affect your ability to drive or use machines.

Fasenra contains polysorbate 20

This medicine contains 0.06 mg of polysorbate 20 (of vegetable origin) in each 30 mg pre-filled pen. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergy.

3. How to use Fasenra Pen

Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.

Asthma

The recommended doseis one 30 mg injection. The first 3 injections are given every 4 weeks. After that, the injections are given every 8 weeks.

EGPA

The recommended doseis one 30 mg injection every 4 weeks.

Fasenra is given by injection just under the skin (subcutaneously). You and your doctor or nurse should decide if you should inject Fasenra yourself. You should not inject Fasenra yourself if you have not received Fasenra before, or if you have had a previous allergic reaction with Fasenra.

You or your caregiver should receive training on the correct way to inject Fasenra. Read the ‘Instructions for Use’ for the pre-filled pen carefully before using Fasenra.

If you miss a dose of Fasenra

If you have missed a dose of Fasenra, talk to your doctor, pharmacist or nurse as soon as possible.

If you stop treatment with Fasenra

Do not stop treatment with Fasenra unless your doctor recommends it. Stopping or interrupting treatment with Fasenra may cause your symptoms to come back and asthma to worsen.

If your asthma symptoms get worse while you are receiving Fasenra injections, talk to your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious allergic reactions

See a doctor immediatelyif you think you may be having an allergic reaction. These reactions can happen hours or days after the injection.

Frequency not known(cannot be estimated from the available data):

  • anaphylaxis

Common symptoms include:

  • swelling of the face, tongue or mouth
  • breathing problems
  • fainting, dizziness, lightheadedness (due to a drop in blood pressure)

Common(may affect up to 1 in 10 people)

  • hypersensitivity reactions (hives, skin rash)

Other side effects

Common(may affect up to 1 in 10 people)

  • headache
  • pharyngitis (sore throat)
  • fever (high temperature)
  • reaction at the injection site (e.g. pain, redness, itching, swelling near the injection site)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Fasenra Pen

Keep this medicine out of the sight and reach of children.

Fasenra Pen is for single use.

Do not use this medicine after the expiry date which is stated on the label and carton after ‘EXP’. The expiry date is the last day of the month shown.

Store in the original package to protect from light.

Store in a refrigerator (2°C to 8°C).

Fasenra Pen can be stored at room temperature (up to 25°C) for a maximum of 14 days. After removal from the refrigerator, Fasenra should be used within 14 days or discarded, and the discard date should be written on the carton.

Do not shake, freeze or expose to heat.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Contents and Additional Information

Fasenra Pen Composition

The active ingredient is benralizumab. A 1 ml pre-filled pen contains 30 mg of benralizumab.

The other components are histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20 (E 432), and water for injectable preparations.

Product Appearance and Container Contents

Fasenra is a solution whose color varies between colorless and yellow. It may contain particles.

Fasenra is available in a container that contains a pre-filled pen.

Marketing Authorization Holder

AstraZeneca AB

SE-151 85 Södertälje

Sweden

Manufacturer

AstraZeneca AB

Gärtunavägen

SE-152 57 Södertälje

Sweden

MedImmune UK Ltd

6 Renaissance Way

Liverpool, L24 9JW

United Kingdom

AstraZeneca Nijmegen B.V., Nijmegen

Lagelandseweg 78

Nijmegen, 6545CG

Netherlands

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:

België/Belgique/Belgien

AstraZeneca S.A./N.V.

Tel: +32 2 370 48 11

Lietuva

UAB AstraZeneca Lietuva

Tel: +370 5 2660550

Text in Bulgarian language with company name AstraZeneca Bulgaria EOOD and phone number +359 24455000

Luxembourg/Luxemburg

AstraZeneca S.A./N.V.

Tél/Tel: +32 2 370 48 11

Ceská republika

AstraZeneca Czech Republic s.r.o.

Tel: +420 222 807 111

Magyarország

AstraZeneca Kft.

Tel.: +36 1 883 6500

Danmark

AstraZeneca A/S

Tlf.: +45 43 66 64 62

Malta

Associated Drug Co. Ltd

Tel: +356 2277 8000

Deutschland

AstraZeneca GmbH

Tel: +49 40 809034100

Nederland

AstraZeneca BV

Tel: +31 85 808 9900

Eesti

AstraZeneca

Tel: +372 6549 600

Norge

AstraZeneca AS

Tlf: +47 21 00 64 00

Ελλάδα

AstraZeneca A.E.

Τηλ: +30 210 6871500

Österreich

AstraZeneca Österreich GmbH

Tel: +43 1 711 31 0

España

AstraZeneca Farmacéutica Spain, S.A.

Tel: +34 91 301 91 00

Polska

AstraZeneca Pharma Poland Sp. z o.o.

Tel.: +48 22 245 73 00

France

AstraZeneca

Tél: +33 1 41 29 40 00

Portugal

AstraZeneca Produtos Farmacêuticos, Lda.

Tel: +351 21 434 61 00

Hrvatska

AstraZeneca d.o.o.

Tel: +385 1 4628 000

România

AstraZeneca Pharma SRL

Tel: +40 21 317 60 41

Ireland

AstraZeneca Pharmaceuticals (Ireland) DAC

Tel: +353 1609 7100

Slovenija

AstraZeneca UK Limited

Tel: +386 1 51 35 600

Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika

AstraZeneca AB, o.z.

Tel: +421 2 5737 7777

Italia

AstraZeneca S.p.A.

Tel: +39 02 00704500

Suomi/Finland

AstraZeneca Oy

Puh/Tel: +358 10 23 010

Κύπρος

Αλκήτωρ Φαρμακευτική Λτδ

Τηλ: +357 22490305

Sverige

AstraZeneca AB

Tel: +46 8 553 26 000

Latvija

SIA AstraZeneca Latvija

Tel: +371 67377100

United Kingdom (Northern Ireland)

AstraZeneca UK Ltd

Tel: +44 1582 836 836

Date of Last Revision of this Leaflet:

Detailed information on this medicinal product is available on the European Medicines Agency website: https://www.ema.europa.eu.

<---------------------------------------------------------------------------------------------------------------->

Instructions for Use

Fasenra 30 mg solution for injection in pre-filled pen

benralizumab

For subcutaneous injection

Single-use pre-filled pen

Before starting to use Fasenra Pen, a healthcare professional should have taught you or your caregiver how to use it correctly.

Read these “Instructions for Use” before starting to use Fasenra Pen and each time you have to perform a new injection.There may be new information. This information does not replace consultation with your healthcare professional regarding your disease or treatment.

If you or your caregiver have any questions, consult your healthcare professional.

Important Information

Keep Fasenra in a refrigerator between 2°C and 8°C in its carton until you are ready to use it.Fasenra may be kept at room temperature up to 25°C for a maximum of 14 days. After removal from the refrigerator, Fasenra must be used within 14 days or discarded.

Do not useyour Fasenra Pen if:

  • it has been frozen
  • it has been dropped or damaged
  • the security seal of the carton has been broken
  • the expiration date (EXP) has passed

Do not:

  • shake your Fasenra Pen
  • share or reuse your Fasenra Pen

If any of the above occurs, discard Fasenra Pen in a puncture-resistant sharps container and use a new pre-filled pen.

Each Fasenra Pen contains 1 dose of Fasenra, which is for single use.

Keep Fasenra and all medicines out of the sight and reach of children.

Your Fasenra Pen

Do notremove the cap until you have reached step 6 of these instructions and are ready to inject Fasenra.

Window of view with bold and italic text showing the words

After use

Pre-filled syringe with pink liquid and white plunger visible through the transparent cylinder

Text that says Liquid Medicine in black letters on a white backgroundWhite rectangular label with black text indicating “Expiration Date Label”

Pre-filled device with transparent cylinder showing blue liquid and purple metal plunger

Text indicating “Green Plunger” with black letters on a white backgroundTransparent plastic protector covering the metal needle of a medical syringe

Step 1 – Gather materials

  • 1 Fasenra Pen from the refrigerator
  • 1 alcohol swab
  • 1 cotton ball or gauze
  • 1 sharps container.

(See step 10 – Dispose of the Fasenra pen safely)

White rectangular package with rounded edges and superimposed layers indicating sealed protection

Two overlapping white ovals partially forming an abstract shape similar to a kidney

Rigid red container for hazardous waste with black biological hazard symbol visible on the front

Pre-filled pen

Alcohol swab

Cotton ball or gauze

Sharps container

Step 2 – Prepare to use your Fasenra Pen

Check the expiration date (EXP).Do not use it if the expiration date has passed.

Before administration, let the pre-filled pen reach room temperature of 20°C to 25°C by leaving the carton out of the refrigerator for approximately 30 minutes.

Do not heatthe Fasenra pen in any other way. For example, do not heat it in a microwave or with hot water, nor place it near heat sources.

Use Fasenra within 14 days of removal from the refrigerator.

Do notremove the cap until step 6

Circular timer with bold number 30 and inscription min showing elapsed time in blue

Step 3 – Check the liquid

Pen injector with transparent cartridge and push button held by a skin-colored hand

Look at the Fasenra Pen liquid through the window of view.The liquid should be clear and colorless to yellowish. It may contain small white particles.

Do notinject Fasenra if the liquid is cloudy, discolored, or contains large particles.

You may see a small air bubble in the liquid. This is normal. You do not need to do anything about it.

Step 4 – Choose the injection site

Black text that says exclusive area for the caregiver on a white backgroundBody diagram showing shaded areas of application on thighs, abdomen, and hips

The recommended injection site is the front of the thigh. You may also use the lower abdomen.

Do notinject it:

  • within 5 cm around the navel
  • where the skin is softened, burned, scaled, or hardened
  • in scars or damaged skin
  • through clothing

A caregiver may inject it into the upper arm, thigh, or abdomen. Do notattempt to inject it yourself into the upper arm. For each injection, choose a different site, separated by at least 3 cm from the site of the previous injection.

Step 5 – Clean the injection site

Hand holding a white gauze pressing on the injection site on light skin

Wash your hands well with soap and water.

Clean the injection site with an alcohol swab in a circular motion. Let it air dry.

Do nottouch the cleaned area before injection.

Do notfan or blow on the cleaned area.

Step 6 – Remove the cap

Hands holding an injection device with a connected needle and an arrow indicating the direction of connection

Hold Fasenra Pen with one hand. Carefully pull the cap off with the other hand.

Set the cap aside to discard it later.

The green needle protector is now exposed. It is there to prevent you from touching the needle.

Do notattempt to touch the needle or push the needle protector with your finger.

Do notattempt to put the cap back on Fasenra Pen. It may cause an early injection or damage the needle.

Complete the following steps directly after removing the cap.

Step 7 – Inject Fasenra

Follow the instructions of your healthcare professional on how to inject. You can either gently pinch the injection site or administer the injection without pinching the skin.

Inject Fasenra following the steps of figures a, b, c, and d.

Keep Fasenra Pen in place for the complete injection.

Do notchange the position of Fasenra Pen after the injection has started.

Hand holding a purple auto-injector pressing against the abdomen at a 90-degree angle

Position Fasenra Pen at the injection site.

Place the Fasenra Pen needle protector straight (at a 90-degree angle) against your skin. Make sure you can see the window of view.

Hand holding a purple auto-injector pressing against the abdomen with an arrow indicating the direction of injection

Hand holding a purple auto-injector pressing against the abdomen with a timer showing 15 seconds

Hand holding a purple injection device pressing against the abdomen with an arrow pointing upwards

Press down firmly. You will hear a click. A “click”indicates that the injection has started. The green plunger will move down in the window of view during the injection.

Hold firmly in place for 15 seconds.

You will hear a second “click”. The second click indicates that the injection is complete. The green plunger will fill the window of view completely.

Lift the Fasenra Pen straight up.

The needle protector will slide down and lock, covering the needle.

Step 8 – Check the window of view

Injectable pen with dose indicator and hands holding it preparing for administration

Check the window of view to make sure all the liquid has been injected.

If the green plunger does not fill the window of view completely, you may not have received the full dose. If this happens or you have any other concerns, call your healthcare professional.

Before injection

Gray rectangular auto-injector with red sliding button inside a magenta circle

Auto-injector with progress indicator in green and silver body inside a red circle

After injection

Step 9 – Check the injection site

Hand pressing a white cotton ball on the skin after a subcutaneous injection

There may be a small amount of blood or liquid where you injected. This is normal.

Gently press on the skin with a cotton ball or gauze until the bleeding stops.

Do notrub the injection site.

If necessary, cover the injection site with a small bandage.

Step 10 – Dispose of the used Fasenra pen safely

Purple and white injector pen on a red biological waste container with hazard symbol

  • Each Fasenra Pen contains a single dose of Fasenra and cannot be reused.
  • Place your used Fasenra Pen in a puncture-resistant sharps containerimmediately after use.

Do notthrow the Fasenra Pen in your household trash.

Discard the cap and any other used materials in your household trash.

Disposal Guide

Dispose of the container as a whole according to the instructions of your healthcare professional or pharmacist.

Do notrecycle your sharps container.

Online doctors for FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN

Discuss questions about FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Марія Мартеллі

Anaesthesiology 12 years exp.

Dr Maria Martelli is a medical doctor specialising in anaesthesiology and pain medicine. She provides online consultations for adults, focusing on the assessment and management of acute, chronic, and complex pain conditions, as well as supportive care in serious illness.

She graduated from the Medical University of Silesia in Katowice and completed her specialisation in Anaesthesiology and Intensive Care. Alongside hospital work, she has extensive experience in home and inpatient hospice care, supporting patients with severe pain and advanced disease. Since 2021, she has been a certified specialist and continues to work in anaesthesiology, intensive care, and pain treatment.

Patients consult her for:

  • Chronic pain lasting more than 3 months (musculoskeletal, neuropathic, mixed pain).
  • Acute pain requiring medical assessment and treatment planning.
  • Post-operative pain and recovery support.
  • Cancer-related pain and symptom relief.
  • Palliative care support and quality-of-life improvement.
  • Adjustment and optimisation of pain medication.
  • Second opinions for complex or treatment-resistant pain.
Dr Martelli takes a structured, evidence-based approach, carefully analysing symptoms, previous treatments, and overall health status. Her consultations focus on realistic pain control goals, safety of therapy, and improving daily functioning.

She is especially attentive to patients living with long-term pain or serious illness, providing clear explanations, compassionate guidance, and medically sound recommendations adapted to each individual situation.

Camera Book a video appointment
€99
5.0 (2)
Doctor

Alexander Nazarchuk

Allergology 7 years exp.

Dr. Alexander Nazarchuk is a physician specialising in allergology and internal medicine. He provides online consultations for adults, following the principles of evidence-based medicine — no outdated treatments or unnecessary tests, with clear explanations and a personalised approach. He helps patients with a wide range of allergic and therapeutic conditions, from common day-to-day complaints to complex cases involving allergies, gastrointestinal issues, cardiovascular concerns, respiratory symptoms, and more.

You can consult Dr. Nazarchuk for:

  • Test interpretation and guidance on diagnostic plans.
  • Allergic rhinitis, hay fever, bronchial asthma (including severe cases).
  • Food and drug allergies, skin rashes, angioedema.
  • Atopic dermatitis, urticaria, contact allergies.
  • Allergen-specific immunotherapy (AIT) – initiation and ongoing management.
  • Abdominal pain, bloating, changes in bowel habits, nausea, heartburn.
  • High blood pressure and adjustment of baseline antihypertensive therapy.
  • Hyperlipidaemia and elevated cholesterol.
  • Cough, nasal congestion, fever, sore throat.
  • Anaemia, including iron deficiency and related conditions.
  • Other issues related to allergology and internal medicine.

During consultations, Dr. Nazarchuk takes a thorough, structured approach — analysing symptoms, identifying potential causes, and helping patients make informed decisions. Whether treatment, further investigation, or monitoring is needed, he explains each step clearly so you understand your health and how best to manage it.

Camera Book a video appointment
€55
0.0 (0)
Doctor

Марта Регеро Капілья

Allergology 8 years exp.

Dr Marta Reguero Capilla is an allergist and immunologist who works with both adults and children. She specialises in the diagnosis, treatment, and ongoing management of allergic and immune-related conditions through online consultations.

In her practice, Dr Reguero Capilla helps patients understand the causes of their symptoms, review test results, and choose appropriate treatment or monitoring strategies. Her consultations are suitable both for first-time assessments and for follow-up care over time.

Patients commonly consult Dr Marta Reguero Capilla for:

  • allergic rhinitis, seasonal allergies, and perennial allergy symptoms;
  • allergic conditions in adults and children;
  • bronchial asthma and allergy-related respiratory symptoms;
  • urticaria (acute and chronic) and angioedema;
  • food allergies and reactions to foods, additives, or medications;
  • atopic dermatitis, allergic rashes, and persistent itching;
  • unexplained or recurrent allergic reactions;
  • interpretation of laboratory tests, allergy testing, and immunology results;
  • immune system concerns, frequent infections, and reduced immune response;
  • ongoing medical follow-up and treatment adjustment.
Dr Reguero Capilla works in a structured and attentive manner, explaining medical decisions clearly and helping patients make informed choices about their own health or their child’s care.

When clinically appropriate, she may provide recommendations for further tests or referrals that patients can use within Spanish medical networks, including Sanitas and DKV, in accordance with the terms and conditions of those services.

Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN?
FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN?
The active ingredient in FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN is benralizumab. This information helps identify medicines with the same composition but different brand names.
Who manufactures FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN?
FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN is manufactured by Astrazeneca Ab. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to FASENRA 30 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN?
Other medicines with the same active substance (benralizumab) include FASENRA 30 mg Injectable Solution in Pre-filled Syringe, CINQAERO 10 mg/mL concentrate for infusion solution, DAXAS 250 micrograms tablets. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media